High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable [1]

Blood

Volumn 109, Issue 3, 2007, Pages 1334-1335

  Gattermann, Norbert ^a   Billiet, Johan ^b   Kronenwett, Ralf ^b   Zipperer, Esther ^b   Germing, Ulrich ^b   Nollet, Friedel ^b   Criel, Arnold ^b   Selleslag, Dominik ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ANEMIA; BONE MARROW; DNA SEQUENCE; GENE MUTATION; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOSIS;

EID: 33846891352     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-022491     Document Type: Letter

References (10)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
6. Remacha AF, Nomdedeu JF, Puget G, et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2006;91:719-720.
7. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. Prepublished on June 1, 2006, as DOI 10.1182/blood-2006-02-005751. (Now available as Blood. 2006;108:2173-2181.)
8. Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood. 2006;108:1781-1782.
9. Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006;20:1641-1644.
10. Bain B, Vardiman JW, Imbert M, Pierre R. Myelodysplastic/ myeloproliferative disease, unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours; Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 58-59.